Clay Siegall’s contribution to cancer therapy

As the co-founder of Seattle Genetics, Dr Siegall Clay is interested in improving cancer victim’s lives. Currently, he serves as the company’s CEO, president and Chairman of the board. After attaining his PhD, he has tirelessly worked with various research departments. He began as a research investigator at Bristol- Myers Institute. Later elevated to the Principal Scientist, and finally staff at the Biotechnology and Cancer Institute. With the experience and skills, he had, he helped introduced Seattle Genetics. Apart from working on his field of study, he is also an author publishing on matters related to science. He was awarded in 1995 for his work on targeted toxins. In 2002, he was among the young entrepreneurs recognized in health faculty. He has PhD in Genetics and a B.S in Zoology.

Seattle Genetics, as Clay Siegall says is an upcoming global, multi-product firm. Its major plan is to build a firm with the various drugs that are coming up in their pipeline. Clay Siegall is driven by his ambition of dealing with all complexities of global marketing of the new products. He admits that he likes coming up with new drugs thou not that simple to do it. The company is seen progressing well with the sales they have made over the years. For instance, in 2016, sales of about $418 million were recorded. Over the past five years, the stock price has been on the rise. The company aims at making improvements in cancer therapy. To be at the top, he followed footsteps of Art Levinson. He admired him in how Art Levinson came up with Genentech. He monitored how it was structured both internally and externally.

Settle Genetics, concentrated on a certain drug known as an antibody-drug conjugate. The drug aims at antigen which makes the immune system generate antibodies. They attach themselves to cancer cells of Hodgkin lymphoma and produce a toxin to destroy the cells. No harm is caused to the normal tissues during chemotherapy hence an advantage to the patient.

There are various other drugs around 11. If at all the first one does not show any good response then one can opt to use another one. Adectris is also another drug which has been authorized by FDA to treat Hodgkin lymphoma. If it works then, oncologists will prefer to use this drug, and the sale will be increased. Studies on the drug are currently underway. Another drug is 22 ME, dealing with bladder cancer and other types of cancer like urothelial. Last is LIV1, dealing with breast cancer in women.

Find out more about Clay Siegall: